A method of evaluating the effectiveness of antituberculous therapy in patients with genital tuberculosis, comprising carrying out a control for background the immunoassay specific anti-TB treatment, characterized in that at the end of the initial phase of the basic course of TB therapy (60-90 doses antituberculosis drugs) carried 1st control, which comprises determining stimulation of interferon-gamma (IFN-γ) index purified tuberculin (PPD-L), determining the levels of specific immunoglob Linov (IgA, IgM) to Mycobacterium tuberculosis (MBT) by enzyme immunoassay (ELISA), and 2nd control is carried out through 6-11 months after the main TB treatment (intensive phase is from 2 to 4 months - 60-120 doses of TAP + continuation phase of 6-7 months - 180-210 doses of anti-TB drugs), while if the stimulation index of IFN-gamma with PPD-L at the end of the intensive phase of TB treatment was higher than 7, 8 - only on IFN- γ with PPD-L, if the optical density of IgM to the ILO was more than 0,600 - only IgM to the Office, if the optical density n and IgA to the ILO was more than 0,450 - the control is carried out only on IgA to the ILO; while the results of controlled studies recommend: while maintaining the specific immunological parameters at the level that was before the start of TB therapy, or a build-up at the end of the intensive phase (1st control, 60-90 doses of anti-TB drugs) conduct correction of TB treatment ( additional administering to reserve drugs); while reducing the specific immunological parameters below the level being
展开▼
